FOR IMMEDIATE RELEASE March 1, 2018<\/p>\n\n\n\n
Drug screening leader<\/strong> develops custom programs to help employers regulated by the DOT Melbourne, Florida: In response to a new rule from the Department of Transportation (DOT) amending the overall regulation for DOT drug and alcohol testing, 49 CFR Part 40, National Drug Screening is offering custom programs for DOT-regulated employers for compliance with the 49 CFR Part 40 regulations. The new DOT rule affects employers of all sizes who are regulated by all DOT agencies, including FMCSA, FAA, FTA, FRA, PHMSA, and USCG.<\/p>\n\n\n\n Joe Reilly<\/strong>, National Drug Screening\u2019s Founder and CEO, cites that, \u201cNow is the time for DOT drug and alcohol policies to be updated with the provisions of the new final rule. Our custom programs can provide a fully compliant policy to include: a written policy, employee education, supervisor training, access to employee assistance program and drug testing.\u201d Mr. Reilly continues, \u201cAs a consortium\/third party administrator, we offer many services for DOT-regulated employers including random consortium management; random selections; preparation of annual Management Information System (MIS) reports; and coordinating urine collections, laboratory testing, MRO services, alcohol testing, and SAP evaluations.\u201d<\/p>\n\n\n\n National Drug Screening\u2019s custom programs, that help employer<\/strong> regulated by the new DOT rule, are designed to alleviate confusion with regards to compliance. The new DOT drug testing panel is still a 5-panel drug test, but the Opiates panel is now called Opioids and includes codeine, heroin, morphine, oxycodone, oxymorphone, hydrocodone & hydromorphone. Particularly affected are employees with prescriptions for these drugs. The involvement of a Medical Review Officer and the employee\u2019s prescribing physician adds complexity to the steps an employer must follow to be compliant. More information can be found here [link to NDS blog article].<\/p>\n\n\n\n Employers who fall under DOT regulations<\/strong> and are affected by the new DOT rule can work directly with National Drug Screening, Inc. to help ensure continued compliance.<\/p>\n\n\n\n About National Drug Screening, Inc<\/strong>: Located on the east coast of Central Florida, National Drug Screening, Inc. offers nationwide service for drug test result reporting by state of the art MRO services, drug testing software, immediate drug tests, drug & alcohol testing for employees. NDS specializes in Drug Screening, Immediate Testing, Drug-Free Workplace programs, DOT Compliance, Employer Programs, and customized Employer Drug Screening Programs. <\/p>\n\n\n\n Joe Reilly FOR IMMEDIATE RELEASE March 1, 2018 Drug screening leader develops custom programs to help employers regulated by the DOT Melbourne, Florida: In response to a new rule from the Department of Transportation (DOT) amending the overall regulation for DOT drug and alcohol testing, 49 CFR Part 40, National Drug Screening is offering custom programs for […]<\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"50847,51548,50997,51233,50863,51263","_relevanssi_noindex_reason":"","footnotes":""},"categories":[45],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/55027"}],"collection":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/comments?post=55027"}],"version-history":[{"count":0,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/55027\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media?parent=55027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/categories?post=55027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/tags?post=55027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
National Drug Screening, Inc
866-843-4545
joe@nationaldrugscreening.com<\/p>\n","protected":false},"excerpt":{"rendered":"